logo
Legal Challenges Faced by Vape Retailers

Legal Challenges Faced by Vape Retailers

The vaping industry has seen explosive growth over the past decade, with thousands of vape retailers emerging both online and offline. While the market continues to expand, it also faces increasing scrutiny from governments and regulatory agencies worldwide. Vape retailers, in particular, find themselves navigating a complex web of legal challenges that can significantly impact their operations. From age verification to advertising restrictions and compliance with health regulations, these hurdles require strategic foresight and continuous adaptation. This blog explores the most pressing legal challenges faced by vape retailers today.
In today's fast-paced world, technology continues to redefine comfort and efficiency. One such innovation is the Hayati pro max plus 6000, a device designed to enhance your daily experiences through unmatched performance and sleek design. Whether you're at home, on the go, or managing work tasks, this product offers reliability and longevity. Its compact size hides a powerhouse of features that ensure optimal usage throughout the day. From smart compatibility to long-lasting battery life, it stands out as a versatile tool. Ideal for tech enthusiasts and casual users alike, it blends function and style in perfect harmony.
One of the foremost legal obligations for vape retailers is ensuring that their products are not sold to minors. Most countries have laws prohibiting the sale of vape products to individuals under a certain age—typically 18 or 21 years old. For brick-and-mortar stores, this usually involves checking government-issued identification. However, for online retailers, implementing robust age verification systems is more complicated. They must use third-party verification services, request ID uploads, or integrate credit card checks—all of which can deter customers or create friction in the sales process.
Non-compliance with age verification laws can result in severe penalties, including hefty fines, suspension of business licenses, or even criminal charges. Moreover, retailers must also be vigilant about changes in the legal purchasing age, which can vary across states, provinces, or countries.
Marketing vape products is a legal minefield, particularly due to the perceived appeal of these products to youth. Regulations often prohibit advertising that makes vaping appear glamorous, safe, or a healthy alternative to smoking. Many jurisdictions ban vape ads on television, radio, and social media platforms, and restrict in-store promotions or sponsorship of events.
For example, in the United States, the FDA regulates how vape products can be marketed and has issued warning letters to companies that violated advertising laws. In the UK, the Advertising Standards Authority (ASA) prohibits certain types of promotional content. Social media marketing is especially tricky, as influencers and brand ambassadors can unintentionally trigger regulatory breaches by promoting vape products inappropriately.
Retailers must ensure that their advertising strategies are compliant, which often means employing legal counsel to vet campaigns, training staff on permissible language, and keeping abreast of changes in marketing laws.
Vape retailers are also responsible for ensuring that the products they sell adhere to labeling and packaging regulations. These rules typically require clear disclosure of ingredients, nicotine content, health warnings, and usage instructions. Many jurisdictions also mandate child-resistant packaging and prohibit certain designs that might appeal to minors, such as colorful packaging or cartoon characters.
Failure to comply with packaging regulations can lead to product recalls, fines, and reputational damage. Retailers must work closely with manufacturers to ensure all products on their shelves are properly labeled and packaged according to legal standards. They also need to maintain records demonstrating compliance in case of audits or inspections by regulatory bodies.
Opening a vape retail store involves more than just renting space and setting up shop. Retailers must obtain the necessary licenses and permits to legally sell vape products. These requirements vary widely depending on the jurisdiction but may include tobacco retail licenses, state-level permits, and local business licenses.
In addition, local zoning laws may restrict where vape shops can be located, especially near schools, playgrounds, or residential areas. Some cities and municipalities have introduced moratoriums on new vape stores or have imposed caps on the number of licenses issued. Retailers need to conduct thorough legal due diligence before launching a new store to avoid costly legal entanglements.
Product liability is another significant legal concern for vape retailers. If a customer suffers harm due to a defective vape device or contaminated e-liquid, the retailer could be held liable—even if they didn't manufacture the product. Lawsuits over battery explosions, adverse health effects, or contamination have made headlines, putting additional pressure on retailers to ensure product safety.
To mitigate liability risks, retailers must source products from reputable manufacturers, verify compliance with safety standards, and maintain rigorous quality control procedures. Offering refunds or recalls when safety concerns arise and maintaining appropriate liability insurance are also essential protective measures.
Many governments impose excise taxes on vape products, similar to those on tobacco. These taxes vary significantly between regions and can be based on nicotine concentration, volume, or wholesale price. Vape retailers must navigate a labyrinth of tax codes to determine what taxes apply to their products and how to collect and remit them accurately.
Non-compliance with tax regulations can trigger audits, fines, and even criminal prosecution. In addition to federal taxes, many states and local governments have their own excise tax rules, making multi-jurisdictional compliance a daunting task. Retailers often need to hire tax professionals or use specialized software to manage their obligations effectively.
One of the most difficult aspects of operating in the vape retail industry is the constantly evolving legal environment. Laws and regulations are frequently updated in response to public health concerns, lobbying, and political pressures. For example, the U.S. FDA periodically updates its list of approved and prohibited vape products, and countries like Australia and India have banned vaping altogether.
Retailers must stay informed about legal changes at the local, national, and international levels. Joining industry associations, subscribing to legal bulletins, and participating in public consultations can help retailers anticipate and adapt to regulatory shifts. Those who fail to do so risk non-compliance, legal action, or business closure.
Counterfeit vape products pose a legal and ethical challenge for retailers. Selling knock-off or unauthorized products not only exposes retailers to lawsuits from brand owners but also jeopardizes consumer safety. Regulatory agencies have cracked down on retailers found distributing counterfeit products, imposing strict penalties.
Retailers should verify their supply chain and ensure that all products are genuine and properly licensed. This involves vetting suppliers, demanding proof of authenticity, and training staff to recognize counterfeit items. Additionally, protecting their own intellectual property, such as logos or proprietary e-liquid formulas, is equally important for brand integrity and legal defense.
Online vape retailers that ship products across borders must comply with international trade laws, customs regulations, and import/export restrictions. Some countries have banned the importation of vaping products altogether, while others have strict labeling and registration requirements. Navigating these laws requires specialized knowledge and often legal counsel.
Retailers must also be mindful of currency conversion issues, international shipping standards, and the risk of packages being seized at the border. Offering international sales without proper legal vetting can lead to disputes, fines, and the loss of business licenses.
The legal challenges faced by vape retailers are complex, multifaceted, and constantly changing. From age verification and marketing restrictions to product liability and international trade laws, retailers must juggle a wide array of legal responsibilities to remain compliant. Navigating this landscape requires a proactive approach, including legal consultation, staff training, and vigilant compliance monitoring. As regulations continue to evolve, those retailers who stay ahead of the curve will be best positioned to thrive in an increasingly scrutinized industry.
TIME BUSINESS NEWS

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Yahoo

time22 minutes ago

  • Yahoo

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS)1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients," said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. "These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients." This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition studyPSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan)Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT)Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media RelationsE-mail: Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Merck announces data from trial studying KEYTRUDA plus Trodelvy
Merck announces data from trial studying KEYTRUDA plus Trodelvy

Business Insider

time3 hours ago

  • Business Insider

Merck announces data from trial studying KEYTRUDA plus Trodelvy

Merck (MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA plus Trodelvy reduced the risk of disease progression or death by 35% versus KEYTRUDA plus chemotherapy for the first-line treatment of patients with PD-L1+ inoperable locally advanced or metastatic triple-negative breast cancer, TNBC, as determined by an FDA-approved test. KEYTRUDA, when given in combination with Gilead's TROP2 antibody-drug conjugate, ADC, Trodelvy, resulted in a median progression-free survival, PFS, of 11.2 months versus 7.8 months when KEYTRUDA was given in combination with chemotherapy. These data from the pivotal Phase 3 ASCENT-04/KEYNOTE-D19 study will be presented today as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting and were selected for the official ASCO Press Program. A higher objective response rate was observed for the KEYTRUDA plus Trodelvy combination, including 13% and 8% with a complete response, respectively, in the KEYTRUDA plus Trodelvy and KEYTRUDA plus chemotherapy arms. Notably, a substantially longer duration of response was observed with KEYTRUDA plus Trodelvy. Encouraging trends in overall survival were also observed, but data are immature at the time of PFS primary analysis. Overall survival follow-up remains ongoing and will continue to be monitored as a key secondary endpoint.

Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment

Yahoo

time9 hours ago

  • Yahoo

Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment

Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed DXd antibody drug conjugate (ADC) patritumab deruxtecan, intended for treating non-small cell lung cancer (NSCLC). The withdrawal follows discussions with the US Food and Drug Administration (FDA) and topline outcomes from the Phase III trial, HERTHENA-Lung02, which did not meet overall survival (OS) statistical significance. The withdrawal decision was made independently of a complete response letter for the therapy received from the agency in June 2024, relating to an inspection of a third-party manufacturing facility. Discovered by Daiichi Sankyo, the therapy is being co-developed by both companies. The parties have sought approval to treat adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC who have previously undergone two or more systemic treatments. HERTHENA-Lung02 assesses the therapy as a single agent against doublet chemotherapy comprising platinum with pemetrexed induction chemotherapy, followed by pemetrexed maintenance chemotherapy. The safety profile observed in the trial was found to be consistent with prior trials, with no safety concerns. Daiichi Sankyo research and development global head Ken Takeshita said: 'While we are disappointed with the OS results of HERTHENA-Lung02, we are conducting further biomarker analyses to better identify patients that may benefit from patritumab deruxtecan to guide our continued development in lung cancer. 'We remain confident in the broad development programme of this HER3-directed antibody drug conjugate, which currently includes multiple clinical trials across 15 types of cancer.' In October 2023, the companies signed a worldwide partnership to co-develop and commercialise the therapy, along with ifinatamab deruxtecan and raludotatug deruxtecan, with Daiichi Sankyo retaining exclusive rights in Japan. The collaboration expanded in August 2024 to include gocatamig, which will be co-developed and commercialised globally, excluding Japan where MSD holds exclusive rights. "Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store